Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma
about
Cofilin-1 and Other ADF/Cofilin Superfamily Members in Human Malignant CellsNovel roles for ERK5 and cofilin as critical mediators linking ERα-driven transcription, actin reorganization, and invasiveness in breast cancer.Proteomic approaches identify members of cofilin pathway involved in oral tumorigenesis.Loss expression of micro ribonucleic acid (miRNA)-200c induces adverse post-surgical prognosis of advanced stage non-small cell lung carcinoma and its potential relationship with ETAR messenger RNAPKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop.Expression of Cofilin-1 and Transgelin in Esophageal Squamous Cell CarcinomaOverexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancerOverexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.Advances in the proteomic discovery of novel therapeutic targets in cancer.Dichloroacetate induces protective autophagy in LoVo cells: involvement of cathepsin D/thioredoxin-like protein 1 and Akt-mTOR-mediated signaling.SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathwayProteomic biomarkers in lung cancer.Proteome research in urothelial carcinoma.Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma.Overexpression of cofilin correlates with poor survival in breast cancer: A tissue microarray analysis.miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma.Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer.Overexpression of metabolic markers PKM2 and LDH5 correlates with aggressive clinicopathological features and adverse patient prognosis in tongue cancer.RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion.A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling.Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer.Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.[Research Progress of Biomakers Proteomics-based in Lung Cancer].High PKM2 expression is independently correlated with decreased overall survival in hepatocellular carcinoma
P2860
Q28075812-C231B96E-FAC9-4243-9FC3-D0B617493437Q33610918-AB36C957-E0EB-4D6C-8710-2215D8B8F3DAQ34507003-F4A6363D-882D-486D-8146-8F64FFC3B274Q35879380-0EC40782-0176-4CCD-A56F-20F62F48E20EQ35955191-209D0DAB-AA1E-4F2B-9811-ECEB630DF252Q36078400-14E4AE99-F205-4852-8E5A-D6579A38D188Q36166992-7F06FEF8-C5B0-4184-A724-3461548BD3E2Q36213166-6BD6803B-8182-47F9-A7A8-4B18A14B11A1Q36414207-862CD053-C56F-4ABB-B973-B41DF7E1428DQ37260569-4C89CCE3-9C60-4DEA-84BA-6482650C8EE8Q37357063-37B21F92-006F-4E19-8316-BA8FD3458D64Q37680287-62F2C0CE-459B-44BB-A527-A8D91127A143Q38100750-1A2CD688-9A3A-4F26-8687-106A995E9EB9Q38461516-55F2E35A-C648-421B-9A4F-1CC7FFAA3F67Q38484441-4602E4C4-F78D-4839-849C-E68153CFBE15Q38637991-59A33E39-4950-4E55-9E79-EA9E529DC484Q38708241-BB894A8E-2EC6-4FDB-B520-E454EB54EFAEQ38710251-F178B5B9-88EC-4A5A-90DE-0E4AEBEA9D86Q38931288-E07B539F-89CF-47D6-A43B-77544EFF1CD8Q39001463-4831EAFE-63C2-4669-9BE2-5E097A54B771Q41084014-CA0842CE-99EC-44ED-9337-9C6A46CD9475Q47098614-5AD342B4-28DC-4C02-89FF-3DA4E6FBEE74Q49888029-96E047FC-281A-4DF8-B111-B859B475A90AQ51450937-2C479A94-B3F5-4864-B577-153309B66782Q55404931-BA528C75-90C4-481D-BBD9-49A5F5A00F44Q55464368-2B79DD9F-CF43-436F-AE7D-2A8A260E2919Q57165700-D0915165-652E-4082-B99C-1E5F6E85B148
P2860
Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@ast
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@en
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@nl
type
label
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@ast
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@en
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@nl
prefLabel
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@ast
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@en
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@nl
P2093
P2860
P1433
P1476
Comparative proteomic approach ...... s for pulmonary adenocarcinoma
@en
P2093
Ai-ping Tong
Feng-ming Gong
Hong-jun Lin
Hong-li Liao
Liang-xue Zhou
Ming-hai Tang
Xing-chen Peng
Ying-wei Xie
Yu-wei Zhao
Zhi-yong Li
P2860
P304
P356
10.1371/JOURNAL.PONE.0027309
P407
P577
2011-11-08T00:00:00Z